Solicitation of Nominations for Membership on the Lead Exposure and Prevention Advisory Committee (LEPAC), 50129-50130 [2021-19222]
Download as PDF
sradovich on DSKJLST7X2PROD with NOTICES
Federal Register / Vol. 86, No. 170 / Tuesday, September 7, 2021 / Notices
data. You may submit comments on any
topic related to this activity. Comments
received, including attachments and
other supporting materials, are part of
the public record and subject to public
disclosure. Do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
near duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
CDC does not accept comment by email.
Oral Public Comment: The public is
welcome to participate, via Zoom,
during the public comment periods on
September 28, 2021, from 11:30 a.m. to
12:00 p.m., EDT, and on September 29,
2021, from 12:10 p.m. to 12:40 p.m.,
EDT. Please note that the public
comment periods end at the times
indicated above. Each commenter will
be provided up to five minutes for
comment. A limited number of time
slots are available and will be assigned
on a first come-first served basis.
Members of the public who wish to
address the WTCHP STAC during the
oral public comment sessions must sign
up by providing their name and desired
date for commenting to Mia Wallace,
Committee Management Specialist, via
email: MWallace@cdc.gov, or the
addresses section provided in this
notice by September 21, 2021.
Written Public Comment: Written
comments will also be accepted from
those unable to attend the public
session per the instructions provided in
the addresses section above. Written
comments received in advance of the
meeting will be included in the official
record of the meeting. Written
comments received by September 21,
2021 will be provided to the STAC prior
to the meeting. The docket will close on
September 29, 2021.
Policy on Redaction of Committee
Meeting Transcripts (Public Comment):
Transcripts will be prepared and posted
to https://www.regulations.gov within 60
days after the meeting. If a person
making a comment gives their name, no
attempt will be made to redact that
name. NIOSH will take reasonable steps
to ensure that individuals making
public comments are aware that their
comments (including their name, if
VerDate Sep<11>2014
00:30 Sep 04, 2021
Jkt 253001
provided) will appear in a transcript of
the meeting posted on a public website.
Such reasonable steps include a
statement read at the start of the meeting
stating that transcripts will be posted,
and names of speakers will not be
redacted. If individuals in making a
statement reveal personal information
(e.g., medical information) about
themselves, that information will not
usually be redacted. The CDC Freedom
of Information Act coordinator will,
however, review such revelations in
accordance with the Freedom of
Information Act and, if deemed
appropriate, will redact such
information. Disclosures of information
concerning third party medical
information will be redacted.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–19224 Filed 9–3–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Solicitation of Nominations for
Membership on the Lead Exposure and
Prevention Advisory Committee
(LEPAC)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
The Centers for Disease
Control and Prevention (CDC) is
soliciting nominations for membership
on the LEPAC. The LEPAC is composed
of 15 members that are Federal and nonFederal experts in fields associated with
lead screening, the prevention of lead
exposure, and services for individuals
and communities affected by lead
exposure. Nominations are being sought
for individuals with expertise in the
fields of epidemiology, toxicology,
mental health, pediatrics, early
childhood education, special education,
diet and nutrition, and environmental
SUMMARY:
PO 00000
Frm 00118
Fmt 4703
Sfmt 4703
U:\07SEN1.SGM
50129
health. Members may be invited to serve
for three-year terms. Selection of
members is based on candidates’
qualifications to contribute to the
accomplishment of LEPAC objectives.
DATES: Nominations for membership on
the LEPAC must be received no later
than November 1, 2021. Packages
received after this time will not be
considered for the current membership
cycle.
ADDRESSES: All nominations should be
emailed to LEPAC@cdc.gov.
FOR FURTHER INFORMATION CONTACT: Paul
Allwood, Ph.D., M.P.H., Designated
Federal Officer, National Center for
Environmental Health, CDC, 4770
Buford Highway NE, Atlanta, GA
30329–4018, Telephone: (770) 488–
6774, PAllwood@cdc.gov.
SUPPLEMENTARY INFORMATION: The
members of this committee are selected
by the Secretary of the U.S. Department
of Health and Human Services (HHS).
The committee’s objective is to advise
the Secretary, HHS and the Director,
Centers for Disease Control and
Prevention/Administrator, Agency for
Toxic Substances and Disease Registry
on a range of activities to include: (1)
Review of Federal programs and
services available to individuals and
communities exposed to lead; (2) review
of the current research on lead exposure
to identify additional research needs;(3)
review of and identification of best
practices, or the need for best practices
regarding lead screening and the
prevention of lead exposure; (4)
identification of effective services,
including services relating to healthcare,
education, and nutrition for individuals
and communities affected by lead
exposure and lead poisoning, including
in consultation with, as appropriate, the
lead exposure registry as established in
Public Law 114–322 Section 2203(b) (42
U.S.C. 300j-27); and (5) undertaking of
any other review or activities that the
Secretary determines to be appropriate.
Annually as determined necessary by
the Secretary or as required by Congress,
the committee shall submit a report to
include: (1) An evaluation of the
effectiveness of the Federal programs
and services available to individuals
and communities exposed to lead; (2) an
evaluation of additional lead exposure
research needs; (3) an assessment of any
effective screening methods or best
practices used or developed to prevent
or screen for lead exposure; (4) input
and recommendations for improved
access to effective services relating to
health care, education, or nutrition for
individuals and communities impacted
by lead exposure; and (5) any other
recommendations for communities
07SEN1
sradovich on DSKJLST7X2PROD with NOTICES
50130
Federal Register / Vol. 86, No. 170 / Tuesday, September 7, 2021 / Notices
affected by lead exposure, as
appropriate.
At least half of the committee will
consist of Federal representatives from a
range of agencies that may include the
Department of Housing and Urban
Development; the Environmental
Protection Agency; the Consumer
Product Safety Commission; the Centers
for Medicare and Medicaid Services; the
Health Resources and Services
Administration; the Food and Drug
Administration; the U.S. Department of
Agriculture; the Occupational Safety
and Health Administration; the National
Institute of Environmental Health
Sciences; the U.S. Geological Survey;
and such additional federal, state, tribal,
and local public and private officials as
the Secretary deems necessary for the
committee to carry out its function. The
rest of the committee will consist of
non-Federal members. Only non-Federal
members are being solicited with this
announcement.
The U.S. Department of Health and
Human Services policy stipulates that
committee membership be balanced in
terms of points of view represented, and
the committee’s function. Appointments
shall be made without discrimination
on the basis of age, race, ethnicity,
gender, sexual orientation, gender
identity, HIV status, disability, and
cultural, religious, or socioeconomic
status. Nominees must be U.S. citizens
and cannot be full-time employees of
the U.S. Government. Current
participation on federal workgroups or
prior experience serving on a federal
advisory committee does not disqualify
a candidate; however, HHS policy is to
avoid excessive individual service on
advisory committees and multiple
committee memberships.
Committee members are Special
Government Employees, requiring the
filing of financial disclosure reports at
the beginning and annually during their
terms. CDC reviews potential candidates
for LEPAC membership each year and
provides a slate of nominees for
consideration to the Secretary of HHS
for final selection. HHS notifies selected
candidates of their appointment as soon
as the HHS selection process is
completed. Note that the need for
different expertise varies from year to
year and a candidate who is not selected
in one year may be reconsidered in a
subsequent year. Candidates should
submit the following items:
• Current curriculum vitae, including
complete contact information
(telephone numbers, mailing address,
email address).
• At least one letter of
recommendation from person(s) not
employed by the U.S. Department of
VerDate Sep<11>2014
00:30 Sep 04, 2021
Jkt 253001
Health and Human Services.
(Candidates may submit letter(s) from
current HHS employees if they wish,
but at least one letter must be submitted
by a person not employed by an HHS
agency (e.g., CDC, NIH, FDA, etc.)
Nominations may be submitted by the
candidate him- or herself or by the
person/organization recommending the
candidate.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2021–19222 Filed 9–3–21; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2021–N–0929]
Food and Drug Administration New Era
of Smarter Food Safety Summit on ECommerce; Public Meeting; Request
for Comments
AGENCY:
Food and Drug Administration,
HHS.
Notice of public meeting;
request for comments.
ACTION:
The Food and Drug
Administration (FDA or we) is
announcing a virtual public meeting
entitled ‘‘FDA New Era of Smarter Food
Safety Summit on E-Commerce:
Ensuring the Safety of Foods Ordered
Online and Delivered Directly to
Consumers.’’ The purpose of the public
meeting is to engage with stakeholders
and invite input on various topics
pertaining to the implementation of
Core Element 3.1 of the New Era of
Smarter Food Safety Blueprint. We
intend to use information resulting from
the public meeting to determine what
action(s), if any, should be taken to help
ensure the safe production and delivery
of human and animal foods sold
through new e-commerce business
models.
SUMMARY:
The public meeting will be held
over 3 days on October 19, 2021, from
11:30 a.m. to 5:30 p.m. Eastern Time;
DATES:
PO 00000
Frm 00119
Fmt 4703
Sfmt 4703
U:\07SEN1.SGM
October 20, 2021, from 11:30 a.m. to
5:15 p.m. Eastern Time, and October 21,
2021, from 11:30 a.m. to 3:45 p.m.
Eastern Time. Submit either electronic
or written comments on this public
meeting by November 20, 2021. See
‘‘Participating in the Public Meeting’’ in
the SUPPLEMENTARY INFORMATION section
of this document for registration and
other information regarding meeting
participation.
The public meeting will be
held virtually. For more information on
the public meeting, see: https://
www.fda.gov/food/workshops-meetingswebinars-food-and-dietarysupplements/new-era-smarter-foodsafety-summit-e-commerce-ensuringsafety-foods-ordered-online-anddelivered.
You may submit comments as
follows. Please note that late, untimely
filed comments will not be considered.
Electronic comments must be submitted
on or before November 20, 2021. The
https://www.regulations.gov electronic
filing system will accept comments
until 11:59 p.m. Eastern Time at the end
of November 20, 2021. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
ADDRESSES:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
07SEN1
Agencies
[Federal Register Volume 86, Number 170 (Tuesday, September 7, 2021)]
[Notices]
[Pages 50129-50130]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-19222]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Solicitation of Nominations for Membership on the Lead Exposure
and Prevention Advisory Committee (LEPAC)
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Centers for Disease Control and Prevention (CDC) is
soliciting nominations for membership on the LEPAC. The LEPAC is
composed of 15 members that are Federal and non-Federal experts in
fields associated with lead screening, the prevention of lead exposure,
and services for individuals and communities affected by lead exposure.
Nominations are being sought for individuals with expertise in the
fields of epidemiology, toxicology, mental health, pediatrics, early
childhood education, special education, diet and nutrition, and
environmental health. Members may be invited to serve for three-year
terms. Selection of members is based on candidates' qualifications to
contribute to the accomplishment of LEPAC objectives.
DATES: Nominations for membership on the LEPAC must be received no
later than November 1, 2021. Packages received after this time will not
be considered for the current membership cycle.
ADDRESSES: All nominations should be emailed to [email protected].
FOR FURTHER INFORMATION CONTACT: Paul Allwood, Ph.D., M.P.H.,
Designated Federal Officer, National Center for Environmental Health,
CDC, 4770 Buford Highway NE, Atlanta, GA 30329-4018, Telephone: (770)
488-6774, [email protected].
SUPPLEMENTARY INFORMATION: The members of this committee are selected
by the Secretary of the U.S. Department of Health and Human Services
(HHS). The committee's objective is to advise the Secretary, HHS and
the Director, Centers for Disease Control and Prevention/Administrator,
Agency for Toxic Substances and Disease Registry on a range of
activities to include: (1) Review of Federal programs and services
available to individuals and communities exposed to lead; (2) review of
the current research on lead exposure to identify additional research
needs;(3) review of and identification of best practices, or the need
for best practices regarding lead screening and the prevention of lead
exposure; (4) identification of effective services, including services
relating to healthcare, education, and nutrition for individuals and
communities affected by lead exposure and lead poisoning, including in
consultation with, as appropriate, the lead exposure registry as
established in Public Law 114-322 Section 2203(b) (42 U.S.C. 300j-27);
and (5) undertaking of any other review or activities that the
Secretary determines to be appropriate.
Annually as determined necessary by the Secretary or as required by
Congress, the committee shall submit a report to include: (1) An
evaluation of the effectiveness of the Federal programs and services
available to individuals and communities exposed to lead; (2) an
evaluation of additional lead exposure research needs; (3) an
assessment of any effective screening methods or best practices used or
developed to prevent or screen for lead exposure; (4) input and
recommendations for improved access to effective services relating to
health care, education, or nutrition for individuals and communities
impacted by lead exposure; and (5) any other recommendations for
communities
[[Page 50130]]
affected by lead exposure, as appropriate.
At least half of the committee will consist of Federal
representatives from a range of agencies that may include the
Department of Housing and Urban Development; the Environmental
Protection Agency; the Consumer Product Safety Commission; the Centers
for Medicare and Medicaid Services; the Health Resources and Services
Administration; the Food and Drug Administration; the U.S. Department
of Agriculture; the Occupational Safety and Health Administration; the
National Institute of Environmental Health Sciences; the U.S.
Geological Survey; and such additional federal, state, tribal, and
local public and private officials as the Secretary deems necessary for
the committee to carry out its function. The rest of the committee will
consist of non-Federal members. Only non-Federal members are being
solicited with this announcement.
The U.S. Department of Health and Human Services policy stipulates
that committee membership be balanced in terms of points of view
represented, and the committee's function. Appointments shall be made
without discrimination on the basis of age, race, ethnicity, gender,
sexual orientation, gender identity, HIV status, disability, and
cultural, religious, or socioeconomic status. Nominees must be U.S.
citizens and cannot be full-time employees of the U.S. Government.
Current participation on federal workgroups or prior experience serving
on a federal advisory committee does not disqualify a candidate;
however, HHS policy is to avoid excessive individual service on
advisory committees and multiple committee memberships.
Committee members are Special Government Employees, requiring the
filing of financial disclosure reports at the beginning and annually
during their terms. CDC reviews potential candidates for LEPAC
membership each year and provides a slate of nominees for consideration
to the Secretary of HHS for final selection. HHS notifies selected
candidates of their appointment as soon as the HHS selection process is
completed. Note that the need for different expertise varies from year
to year and a candidate who is not selected in one year may be
reconsidered in a subsequent year. Candidates should submit the
following items:
Current curriculum vitae, including complete contact
information (telephone numbers, mailing address, email address).
At least one letter of recommendation from person(s) not
employed by the U.S. Department of Health and Human Services.
(Candidates may submit letter(s) from current HHS employees if they
wish, but at least one letter must be submitted by a person not
employed by an HHS agency (e.g., CDC, NIH, FDA, etc.)
Nominations may be submitted by the candidate him- or herself or by
the person/organization recommending the candidate.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2021-19222 Filed 9-3-21; 8:45 am]
BILLING CODE 4163-18-P